This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Feedback

We welcome your feedback, which will help improve this site.

Feedback form

Performance in Initiating and Delivering Clinical Research (PID) - Submission guidelines

 

Contents

The submissions for Performance in Initiating and Performance in Delivering are now reopen. You are required to submit Q4 19-20, Q1 20-21 and Q2 20-21 data by the 30 October 2020.

Please contact the CTP team at CTP@nihr.ac.uk with any questions or concerns.

 

Version Control

 

Updated for the restart of submissions

 

Items 27, 28

Update of Submission and Publication Timetable

 

Introduction

1. The Government wishes to see a dramatic and sustained improvement in the performance of providers of NHS services in initiating and delivering clinical research. The aim is to increase the number of participants who have the opportunity to participate in research and to enhance the nation’s attractiveness as a host for research.

2. The Government’s Plan for Growth[1], published in March 2011, announced the transformation of incentives at local level for efficiency in initiation and delivery of research.

3. From July 2013 for clinical trials (as defined in the Definitions section of this page), the NIHR has enforced the transparency commitment for this exercise. Providers of NHS services are required to publish information on recruitment to clinical trials and delivery to time and to target for commercial clinical trials. The list of providers and the links to their published data is available here: Publication Information.

4. NHS providers holding NIHR contracts issued after Autumn 2011 are required to provide, on a quarterly basis, information on recruitment to clinical trials, including commercial trials. This applies to all clinical trials hosted by the organisation, as specified in paragraph 11 and paragraph 16. These data must be submitted to the NIHR Central Commissioning Facility (CCF) via the Clinical Trial Performance (CTP) Submission Platform in the format specified in this document.

5. The following organisations may be subject to a LCRN Partner contract, provide services and recruit clinical trial participants, but should not currently submit a return:

  • General Practices
  • Clinical Commissioning Groups

If in doubt, please contact the NIHR-CCF Clinical Trials Performance team.

6. NHS providers are required to publish the information on recruitment to clinical trials and recruitment to time and target for commercial contract clinical trials in an accessible part of their website.  The minimum dataset is listed in paragraph 15 and paragraph 17. Individual NHS providers might wish to consider publishing additional information, especially where they have identified delays to recruitment. The link to the data will be published in the NIHR website. Please provide the URL where the information is published as soon as possible after your webpage goes live and no later than the publication and submission deadline.

7. The collection of NHS provider data on initiating and delivering clinical research, described here, is a separate exercise from the collection of performance data by the NIHR Clinical Research Network (CRN) against the CRN High Level Objectives. However both exercises have, as overall aims, increasing the number of participants able to participate in research, and enhancing the nation’s attractiveness as a host for research and they are based on a common minimum data set for HRA Approval trials.

8. From Quarter 4 2015-16, the submission platform changed to be able to collect information on clinical trials which go through the HRA approval process[2]. The update to the CTP platform reflects the minimum data set developed by CCF, CRN and HRA to provide greater flexibility for understanding performance at all points across set-up the study life-cycle at both a site and study level and provides consistent definitions on which each organisation will base their respective metrics. Further details on how the new metrics will be analysed will be communicated to providers of NHS services in due course.

Further information can be found in supplementary documents and in guidance on HRA approvals and NIHR metrics.

9. From Quarter 1 2017-18, the submission platform will only be accepting information on trials which have gone through the HRA Approval process; all data fields related to the collection of trials with NHS Permission will be removed.

Requirements

10. NHS providers are required to submit information via the NIHR CTP submission platform in two areas:

  • Initiating clinical research
  • Delivering commercial contract clinical research to time and target.

Initiating Clinical Research

11. Providers of NHS services must submit to the CCF, within 30 days of the end of each quarter (see timetable in paragraph 27), the following information for every clinical trial (regardless of funder or inclusion in NIHR CRN Portfolio) where the Date Site Selected falls within the previous twelve months:

  • The Research Ethics Committee (REC) reference number
  • The Integrated Research Application System (IRAS) Number
  • The name of the clinical trial
  • The date the site was invited
  • The date the site was selected
  • The HRA Approval date
  • The date the site was confirmed by the sponsor
  • The date the site was confirmed
  • The non-confirmation status
  • The date when the site is ready to start
  • The date of the recruitment of the first participant to the clinical trial (if this has occurred)
  • If no date of recruitment of the first participant is given, whether the first participant has not yet been recruited or the date of recruitment is not available.

The Department of Health and Social Care is committed to improving clinical trial performance and reducing site set up and participant recruitment time. As of Quarter 1 2018-19, this will no longer be assessed with a 70 day benchmark for the duration between Date Site Selected and date of First Participant Recruitment. A renewed focus will be placed on transparency, accuracy, and meeting sponsor expectations. Please continue to report any and all delays which have affected or may affect agreed study timelines in line with the minimum data set fields outlined above.

If there is a delay in recruiting the first participant into a trial:

  • The reason for any delay in recruiting the first participant into a trial in relation to the site being selected

Please do not submit information on studies for which the NHS provider is only a Patient Identification Centre (PIC)

Please do not include trials in your Performance in Initiating return where your site is being added to an existing study which was brought under HRA Approval after 31 March 2016. Please review the letter of HRA Approval for the trial to see if this applies. The letter will show ‘Pre-HRA’ or will make reference to the trial being ‘brought under HRA Approval’. If you are unsure if your trial falls in to this category, please contact the Clinical Trial Performance Team well in advance of the submission deadline for advice.

12. We recognise that there are a number of reasons why the recruitment of the first participant into clinical trials might be delayed. The main reasons are listed in the "Possible reasons for delays to first participant recruitment" section of this page. One or more appropriate reasons should be selected on the template and any additional information provided in the comments field. Please note that the inclusion of a possible reason for non-compliance on this list does not necessarily mean that this reason will be deemed to be acceptable.  Provision of full data and explanation will help us all identify and clarify recurring issues that partners in the health research system will need to address.

13. NHS Providers are required to report where responsibility for delays sits, when citing possible reasons for delay for Performance in Initiating Clinical Research. The four sources of delay correspond to:

  • NHS (host site)
  • Sponsor (including NHS sponsors)
  • Both NHS and Sponsor
  • Neither NHS (host site) nor Sponsor

For example:

  • Delayed HRA Approval would correspond to Neither NHS (host site) nor Sponsor.
  • Delayed delivery of IMP would (normally) correspond to Sponsor delay.
  • Costing and Contractual negotiation would (normally) correspond to either/or Both NHS and trial Sponsor.
  • Staff absence or shortage resulting in delayed confirmation of capacity and capability would (normally) correspond to NHS (host site)
  • Some delays, such as rare or very rare disease [3], correspond to Neither

14. For additional information regarding sources of delay for trials, please refer to the feedback document available on the NIHR website here: PID Feedback Document.

15. For Performance in Initiating Clinical Research, NHS providers shall publish, in an accessible part of their website and within 30 days from the end of the quarter, the following information for every clinical trial where the Date Site Selected falls within the previous twelve months:

  • The Research Ethics Committee (REC) reference number
  • The Integrated Research Application System (IRAS) Number
  • The name of the clinical trial
  • The date the site was invited
  • The date the site was selected
  • The HRA Approval date
  • The date the site was confirmed by the sponsor
  • The date the site was confirmed
  • The date when the site is ready to start
  • The date of the recruitment of first participant, and
  • The source of the delay in recruiting the first participant into a trial (NHS Provider/ Sponsor/ Both/ Neither).

Plus, in the event that a trial initiation did not proceed to confirmation:

  • The non-confirmation status.

Delivering Clinical Research

16. NHS providers must submit to the CCF, within 30 calendar days of the end of each quarter (see timetable in paragraph 27), the following information for every commercial contract clinical trial hosted by the NHS provider closed to recruitment in the previous twelve months.

Please do not submit information on studies for which the NHS provider is only a Patient Identification Centre (PIC).

From Quarter 4 2015-16, providers must submit the following information only for trials closed to recruitment in the previous 12 months:

  • The Research Ethics Committee (REC) reference number
  • The Integrated Research Application System (IRAS) Number  
  • The name of the clinical trial
  • Whether or not a target number of participants was agreed
  • The minimum number of participants agreed to be recruited (if a range has been agreed; this will be the same as the maximum if a fixed number has been agreed)
  • The maximum number of participants agreed to be recruited (if a range has been agreed; this will be the same as the minimum if a fixed number has been agreed)
  • Whether or not a target date to recruit participants was agreed 
  • The date agreed to recruit the target number of participants      
  • The total number of participants recruited at the agreed target date
  • The total number of study participants recruited 
  • The date that the trial closed to recruitment       
  • The reason for the closure of the trial

17. For Performance in Delivering Clinical Research the Contractor shall publish, in an accessible part of their website and within 30 days from the end of the quarter, the following information for every commercial contract clinical trial hosted by the NHS provider closed to recruitment in the previous twelve months:

  • The Research Ethics Committee (REC) reference number
  • The Integrated Research Application System (IRAS) Number  
  • The name of the clinical trial
  • Whether or not a target number of participants was agreed
  • The minimum number of participants agreed to be recruited (if a range has been agreed; this will be the same as the maximum if a fixed number has been agreed)
  • The maximum number of participants agreed to be recruited (if a range has been agreed; this will be the same as the minimum if a fixed number has been agreed)
  • Whether or not a target date to recruit participants was agreed 
  • The date agreed to recruit the target number of paticipants       
  • The total number of participants recruited at the agreed target date     
  • The total number of study participants recruited
  • The date that the trial closed to recruitment       
  • The reason for the closure of the trial

Publication Transparency

18. For the publication of data for initiation and delivery of clinical research, the clinical trial data and associated statistics and descriptive information provided to the public via web pages should reflect the data submitted in the quarterly submission to CCF.

19. Where NHS Providers are submitting and publishing data for fifty clinical trials or more and publications are in PDF or Word format, it is requested that these data records be sequentially numbered (i.e. 1-51) for the efficiency and accuracy of comparing submission data to those data published on Trust websites.

20. Where NHS Providers have submitted a nil return for Performance in Initiating or Performance in Delivering, or both, it is requested that this is clearly stated on the Trust website.

21. If the website address of the Trust has changed, the provider must inform the CTP team in advance of the publication deadline.

Submission of information

22. The NIHR CCF CTP Submission Platform (https://ccfctp.nihr.ac.uk) has been created for NHS providers to submit their information.  The CCF will provide each NHS provider that is required to submit information with the necessary information to log in and upload data on initiating and delivering clinical research.

23. Platform Users should attempt to enter and validate some data in advance of the submission deadline so that any technical issues can be addressed without delaying returns. If the NHS Provider does not host any clinical trials, they are still required to “submit” an empty return.

24. CTP Submission Platform Instructions accompany these Performance in Initiating and Delivering Clinical Research Submission Guidelines.

25. NHS Providers are responsible for verifying that their data has been successfully submitted each quarter and that it is true and accurate to the best of their knowledge. If the NHS Providers experience issues with the platform, they must contact the CTP team well in advance of the deadline.

26. Any queries on the format of the data or the submission process should be directed to the CCF at CTP@nihr.ac.uk .

Submission and publication timetables

The submissions for Performance in Initiating and Performance in Delivering are now reopen. You are required to submit Q4 19-20, Q1 20-21 and Q2 20-21 data by the 30 October 2020.

Please see below the submission periods for the requested quarters:
 
 
Q4 19-20 01 April 2019 - 31 March 2020
Q1 20-21 01 July 2019 - 30 June 2020
Q2 20-21 01 October 2019 - 30 September 2020
 
All three submissions are due by 30 October 2020. Please complete and submit them in order, i.e., do not start Q1 until Q4 has been successfully submitted.

Please contact the CTP team at CTP@nihr.ac.uk with any questions or concerns.

 

Further information

29. Definitions of the terms used in this document are provided in the Definitions section of this page. 

30. Further information on this exercise, including details on comparable performance in initiation of clinical research and a trend analysis can be found here.

Getting in touch

31 Enquiries should be sent to the NIHR Central Commissioning Facility at CTP@nihr.ac.uk.

Róisín Tooke-Mitchell, Senior Analyst – 020 8843 7102

Adam Judd, Data Analyst – 020 8843 8059

 

Definitions

Term

Definition

Format

Clinical Trial

A set of medical research procedures conducted on human participants to allow safety and adverse effects of interventions, their efficacy, or their effectiveness to be established often by comparison with alternative or placebo/sham interventions. Interventions may be drugs, diagnostics, prophylactics, surgery, devices, non-invasive therapies, screening or other healthcare procedures or technologies.

This definition does not just refer to studies which fall within the remit of the MHRA; the relevant categories of study in the Integrated Research Application System (IRAS) Project Filter Question 2 (Type of Research) on the IRAS application form, are as follows:

Clinical trial of an investigational medicinal product  

Clinical investigation or other study of a medical device

Combined trial of an investigational medicinal product and an investigational medical device

Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice

 

Research Ethics Committee (REC) Reference Number

The reference number allocated to the trial by the National Research Ethics Service.

Free text

Integrated Research Application System (IRAS) Number

The identifier assigned to a study record in the Integrated Research Application System (IRAS).

Studies without an IRAS ID (i.e., never used IRAS/CSP) should enter 0.

Free text

Name of the Clinical Trial

The full title of the clinical trial, as stated on the Research Ethics Committee form.

Free text

Recruitment of First Participant

The date the first eligible participant consented to the study.

Further context can be found in the Minimum Data Set.

dd/mm/yy

Date Site Invited

The date on the sponsor email received by the site providing the protocol in the version to be submitted for regulatory review.

dd/mm/yy

Date Site Selected

The date on the sponsor email received by the site providing the minimum defined documents to enable site to commence arrangement and/or confirmation of local capacity and capability as applicable representing that the site has been selected to take part in the study.

Clarification of 'Date Site Selected' for sites added to HRA approval studies via amendment: 

The provision of the HRA amendment validation letter does not provide any additional information to enable local capacity and capability activities for a new site added via an amendment.  Sites are expected to commence arranging local capacity and capability based on the local information pack from the sponsor which reflects the current document versions, including any submitted with the amendment to the HRA.  This pack does not need to include the HRA amendment validation letter. The date of sending of the pack should be reflected in the 'Date Site Selected' data field.  Local set-up is expected to commence prior to HRA Approval and therefore the same principle applies to amendments: the site should issue confirmation of capacity and capability (where required) once the HRA has approved the amendment.  For the purpose of completing PID returns, if a delay in completing site set-up occurs as a result of HRA amendment processing, this can be captured by selecting ‘A – Permissions Delayed/Denied’ and including a brief explanation in the comments section. 

dd/mm/yy

HRA Approval Date

The date of HRA approval for the study, as per the HRA Approval Letter

dd/mm/yy

Date Site Confirmed by Sponsor

The date of the first contract signature of all the organisations involved (i.e., sponsor, site, third party) or date on the email received from the sponsor providing the final statement of activity ready for final agreement.

dd/mm/yy

Date Site Confirmed

The date of the last contract signature of all the organisations involved (i.e. sponsor, site, third party) or date of final written agreement of statement of activity, as applicable.

dd/mm/yy

Non-Confirmation Status

The reason why the site was not confirmed, where applicable. This is a drop-down field with the following options:

Sponsor declined site confirmation

Site declined to participate

Drop-down

Date Site ready to start

The date that the site is ready to start (i.e., recruit study participants, provide data or tissue) defined by all other requirements to start, additional to contract signature and/or Statement of Activity agreement, are satisfied.

dd/mm/yy

Commercial Contract Clinical Trial

A clinical trial that is solely funded and sponsored by industry in which:

The trial sponsor is the industrial company

The trial is carried out with the aim of generating data for purposes such as Marketing Authorisations, safety monitoring and supportive evidence for claims

The sponsor owns all the trial data and all Intellectual Property and Know How arising directly from the trial.

 

Target number of participants available

Whether or not the target number of clinical trial subjects to be recruited to participate in the trial has been specified in the relevant Clinical Trials Agreement between the commercial sponsor of the trial and the NHS provider conducting the trial. This field is supplied as a drop-down, with the following options:

Not available/ not agreed

Number agreed

Range agreed

Drop-down

Minimum number of participants agreed

The minimum number of paticipants agreed to be recruited, if a range has been agreed. This will be the same as the maximum if a fixed number has been agreed.

Integer

Maximum number of particpants agreed

The maximum number of participants agreed to be recruited, if a range has been agreed. This will be the same as the minimum if a fixed number has been agreed.

Integer

Target Date To Recruit Partipants Agreed?

Whether or not there is a target date agreed by which the target number of participants must be recruited. This is supplied as a drop-down field, with the following options:

Not available / not agreed

Date agreed

Drop-down

Date Agreed to recruit target number of participants

The date by which the target number of participants must be recruited, if a date has been agreed / is available.

dd/mm/yyyy

Total Number Of Participants Recruited At The Agreed Target Date

The number of participants which were recruited by the target date, if a target date was agreed / is available.

Integer

Total number of study participants recruited

Total number of study participants randomised / recruited into the study at that site.

Integer

Date That The Trial Closed To Recruitment

The date that the trial stopped recruiting participants.

dd/mm/yyyy

Reason for Closure of Trial

The reason why the trial was closed. This is supplied as a drop-down field, with the following options:

Recruitment finished

Withdrawn by Sponsor

Withdrawn by Host

Drop-down

 

Possible reasons for delays to first participant recruitment

In order to facilitate data collection and analysis, a number of possible reasons for delays to first participant recruitment have been provided on the template:

A) Relevant permissions delayed and not granted in time

  • HRA approval process not completed in time
  • Study-wide review not completed in time
  • Local review not completed in time
  • NHS Research Ethics Committee review not completed in time
  • Medicines and Healthcare products Regulatory Agency (MHRA) review not completed in time
  • CE mark process not completed in time
  • Other regulatory reviews not completed in time

B) Study suspended by sponsor

  • Study suspended at all sites
  • Study suspended at this site

C) Study closed by sponsor:

  • Safety reasons
  • Lack of clinical equipoise, as defined by the sponsor
  • Change in development pipeline within sponsor company
  • Strategic/financial reasons within sponsor company
  • Study-wide recruitment completed

D) Delays caused by sponsor:

  • Delay in provision of pharmacy manual
  • Protocol amendments
  • Delayed site initiation visit
  • Delayed confirmation from sponsor of study open to recruitment at site (i.e. delays in receiving “Green Light”)

E) Staff availability issues at site

F) No eligible participants seen during the reported period

  • Participants sought but no eligible participants identified
  • Strict participant eligibility criteria

NB: CCF requires a greater level of detail in the comments section for records where the reason for delay is ‘F-No Participants Seen’ and the source of delay is ‘Neither’ in order to ensure that the actual cause of why no participants were seen (i.e., participants were screened but none were eligible, a small participant population due to tight inclusion/exclusion criteria or rare diseases meant that few participants presented with the condition, etc.) is clear.

G) Eligible participants seen during the relevant period but did not consent to participate in the trial

H) Contracting delays

  • Within NHS provider
  • Within sponsor company
  • Other contracting delays

I) Rare or very rare diseases studies[3]

J) Other (please describe)

In addition NHS providers are now required to identify the source that reasons for delay correspond to (please refer to paragraph 13 for further details).

Please note: Labels for these reasons within the CTP submission platform are abbreviated and vary slightly as stated, though the definitions and letter codes remain the same as described herein.

All relevant reasons for delay should be selected on the template; the reasons for delay can also be expanded upon in the comments section, if desired. Please note that the inclusion of a possible reason for delay on this list does not necessarily mean that this reason will be deemed to be acceptable.

Please find more detailed information regarding reasons for delay, and examples of delays here: PID Feedback document.

 

[1] http://cdn.hm-treasury.gov.uk/2011budget_growth.pdf

[2] See http://www.hra.nhs.uk/about-the-hra/our-plans-and-projects/assessment-approval/ for more information.

[3] A rare disease in Europe is defined by EURORDIS as a disease affecting less than 1 in 2,000 citizens. The NIHR considers a very rare disease as one that affects less than 1 in 100,000 of the general population.